Buenos dias ...
Delcath Systems, Inc. opera como una compañía de dispositivos médicos y farmacéuticos de especialidad se centra en el campo de la oncología. La tecnología de la empresa? S permite la administración de dosis altas de quimioterapia y otros agentes terapéuticoss...
....no se porque pero sube un 30% no ??>>>
Delcath Systems, Inc.
(NASDAQ:DCTH)
https://www.google.com/finance?q=NASDAQ%3ADCTH&ei=cFlJUtiMDqiowAOovgE
Pre-market: 0.391 +0.092 (+30.84%)
coño, una que estoy y sube!!!!!
me has alegrado la mañana, a ver lo que dura!!
DCTH
a ver lo que dura!....dura lo que dure dura !!
yo tambien stoy en ella.
Yo no estoy en el valor, pero no entiendo lo de la subida....
Ojalá sea cierta para los que estais dentro...
La única new que veo, a mi entender, es negativa, ya que parece que le deniegan el status de orphan drug....
http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=405413
CytRx: Aldoxorubicin Data Demonstrates Significant Advantages Over Doxorubicin
RELATED NEWS
CytRx Corp. To Present At Rodman & Renshaw Conference; Webcast At 10:50 AM ET
Trade CYTR now with
9/30/2013 6:11 AM ET
CytRx Corp. (CYTR: Quote) announced compelling preliminary data from its global Phase 2b soft tissue sarcoma trial indicating that patients treated with aldoxorubicin had a significantly higher OVERALL RESPONSE RATE or ORR of 22% as compared to those administered the widely used chemotherapeutic agent doxorubicin with an ORR of 0%.
"Although preliminary, we are certainly optimistic about aldoxorubicin's prospects in soft tissue sarcoma based on the favorable results from our earlier second-line Phase 1b/2 clinical trial in patients who had failed other therapies and these preliminary overall response results as a first-line treatment announced today ," said Executive Vice President and Chief Medical Officer Daniel Levitt.
CytRx announced additional data from a trial in immunodeficient mice transplanted with human glioblastoma cells in their brain that showed those animals treated with aldoxorubicin had a median survival rate of more than 63 days, compared with approximately 25 days for animals treated with doxorubicin or saline.
The company said it plans to initiate a Phase 2 clinical trial in 2013 evaluating the preliminary efficacy of aldoxorubicin in patients with AIDS-related Kaposi's sarcoma, a common HIV-associated tumor. The current standard-of-care for severe dermatological and systemic Kaposi's sarcoma is liposomal doxorubicin (Doxil); however, a significant proportion of patients exhibit minimal to no clinical response to this agent and the drug's toxicity often prevents continued therapy. The Phase 2 trial will enroll up to 30 patients and will be conducted at the LSU Health Science Center in New Orleans.
A ver lo que hace el precio, porqué quizá ya esté descontada la subida, de 2,25 a 3,25 en pocas sesiones...
Voy a intentar entrar en pre a 3,5/3,6, a ver si pudiera pillar una subidita antes de apertura, y salirme con plus....
Un saludo
achn
$ACHN Downgraded to Underperform at Bank of America, PO Lowered to $2
ISCO , alguien pedia info de esta el viernes,
un poco de su pipeline, y el por que me interesa (por sus dos ind de 1q2014 es la respuesta)
mstx esta al saltar
1q 2014 IND , 2 Catalyst $ISCO, PARKINSON and METABOLIC/LIVER DISEASE pic.twitter.com/pK7u6LbgwR
https://twitter.com/inversbio/status/384644154157826049/photo/1
